Related Experiment Video
Updated: May 23, 2025

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins
Published on: October 4, 2017
The Therapeutic Future for Congenital Disorders of Glycosylation
I J J Muffels1, T Kozicz1,2, E O Perlstein3
1Department of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract:
The past decade, novel treatment options for congenital disorders of glycosylation (CDG) have advanced rapidly. Innovative therapies, targeting both the root cause, the affected metabolic pathways, and resulting manifestations, have transitioned from the research stage to practical applications. However, with novel therapeutic abilities, novel challenges await, specifically when it concerns the large number of clinical trials that need to be performed in order to treat all 190 genetic defects that cause CDG known to date. The present paper aims to provide an overview of how the CDG field can keep advancing its therapeutic strategies over the coming years with these challenges in mind. We focus on three important pillars that may shape the future of CDG: the use of disease models, clinical trial readiness, and the possibility to make individualized treatments scalable to the entire CDG cohort.
Related Concept Videos
Inborn Errors of Metabolism
Gene Therapy
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Proteoglycans
Lysosomal Hydrolases
Oligosaccharide Assembly
Multiple sugar molecules that may or may...

